Osaka, Japan

Yoji Oderaotoshi

This inventor holds 2 USPTO granted patents. Top assignees: The University of Tokyo, Towa Pharmaceutical Co., Ltd.. Active years: 2019-2020.


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2019-2020

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yoji Oderaotoshi: Innovator in Proton Pump Inhibitor Compounds

Introduction

Yoji Oderaotoshi is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of proton pump inhibitors. With a total of 2 patents, his work focuses on producing highly pure optically active compounds.

Latest Patents

Oderaotoshi's latest patents include innovative methods for producing proton pump inhibitor compounds with optical activity. His first patent describes a method that allows for the safe and inexpensive production of a highly pure optically active proton pump inhibitor compound. This method involves oxidizing a sulfide with hydrogen peroxide using an iron salt in the presence of a chiral ligand. The second patent reiterates this process, emphasizing the high yield and enantioselectivity achieved through the same innovative approach.

Career Highlights

Throughout his career, Yoji Oderaotoshi has worked with prestigious institutions, including the University of Tokyo and Towa Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical research and development.

Collaborations

Oderaotoshi has collaborated with esteemed colleagues such as Eiichi Nakamura and Laurean Ilies. These partnerships have further enriched his research and innovation in the field.

Conclusion

Yoji Oderaotoshi stands out as a significant figure in the development of proton pump inhibitors, with his innovative methods paving the way for advancements in pharmaceutical chemistry. His contributions continue to impact the industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…